JP2022543021A - がんを処置する方法及び使用 - Google Patents

がんを処置する方法及び使用 Download PDF

Info

Publication number
JP2022543021A
JP2022543021A JP2022506342A JP2022506342A JP2022543021A JP 2022543021 A JP2022543021 A JP 2022543021A JP 2022506342 A JP2022506342 A JP 2022506342A JP 2022506342 A JP2022506342 A JP 2022506342A JP 2022543021 A JP2022543021 A JP 2022543021A
Authority
JP
Japan
Prior art keywords
hhi
cancer
tumor
administered
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022506342A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022543021A5 (cg-RX-API-DMAC7.html
Inventor
メディナ，マヌエル，ヒダルゴ
Original Assignee
ネルム コーポレーション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ネルム コーポレーション filed Critical ネルム コーポレーション
Publication of JP2022543021A publication Critical patent/JP2022543021A/ja
Publication of JP2022543021A5 publication Critical patent/JP2022543021A5/ja
Priority to JP2025093180A priority Critical patent/JP2025143272A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
JP2022506342A 2019-05-29 2020-05-28 がんを処置する方法及び使用 Pending JP2022543021A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025093180A JP2025143272A (ja) 2019-05-29 2025-06-04 がんを処置する方法及び使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962853842P 2019-05-29 2019-05-29
US62/853,842 2019-05-29
PCT/US2020/070080 WO2020243745A1 (en) 2019-05-29 2020-05-28 Methods and uses for treating cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025093180A Division JP2025143272A (ja) 2019-05-29 2025-06-04 がんを処置する方法及び使用

Publications (2)

Publication Number Publication Date
JP2022543021A true JP2022543021A (ja) 2022-10-07
JP2022543021A5 JP2022543021A5 (cg-RX-API-DMAC7.html) 2023-06-06

Family

ID=73553943

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022506342A Pending JP2022543021A (ja) 2019-05-29 2020-05-28 がんを処置する方法及び使用
JP2025093180A Pending JP2025143272A (ja) 2019-05-29 2025-06-04 がんを処置する方法及び使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025093180A Pending JP2025143272A (ja) 2019-05-29 2025-06-04 がんを処置する方法及び使用

Country Status (11)

Country Link
US (1) US11911374B2 (cg-RX-API-DMAC7.html)
EP (1) EP3976036A4 (cg-RX-API-DMAC7.html)
JP (2) JP2022543021A (cg-RX-API-DMAC7.html)
KR (1) KR20220002745A (cg-RX-API-DMAC7.html)
CN (2) CN119326899A (cg-RX-API-DMAC7.html)
AU (1) AU2020283913A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021026294A2 (cg-RX-API-DMAC7.html)
CA (1) CA3141072A1 (cg-RX-API-DMAC7.html)
IL (1) IL288591B2 (cg-RX-API-DMAC7.html)
MX (1) MX2021014686A (cg-RX-API-DMAC7.html)
WO (1) WO2020243745A1 (cg-RX-API-DMAC7.html)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011513199A (ja) * 2008-02-26 2011-04-28 武田薬品工業株式会社 縮合複素環誘導体およびその用途
JP2013503174A (ja) * 2009-08-25 2013-01-31 アブラクシス バイオサイエンス， エルエルシー タキサンおよびヘッジホッグ阻害剤のナノ粒子組成物を使用する併用療法
US20170119740A1 (en) * 2013-11-14 2017-05-04 The Board Of Trustees Of The Leland Stanford Junior University Methods for Treating Cancer by Activation of BMP Signaling

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170326118A1 (en) * 2001-07-02 2017-11-16 Sinan Tas Drug treatment of tumors wherein hedgehog/smoothened signaling is utilized for inhibition of apoptosis of tumor cells
CA2801891C (en) 2010-06-07 2020-10-27 Abraxis Bioscience, Llc Combination therapy methods for treating proliferative diseases
JP2012097032A (ja) * 2010-11-02 2012-05-24 Takeda Chem Ind Ltd 併用医薬
WO2014165644A2 (en) * 2013-04-04 2014-10-09 The General Hospital Corporation Combination treatments with sonic hedgehog inhibitors
US10329304B2 (en) * 2014-09-12 2019-06-25 Vanderbilt University Compounds and methods for inhibition of hedgehog signaling and phosphodiesterase
WO2016141084A1 (en) * 2015-03-03 2016-09-09 The Board Of Trustees Of The Leland Stanford Junior University Producing mesodermal cell types and methods of using the same
WO2017100533A1 (en) * 2015-12-09 2017-06-15 Board Of Regents, The University Of Texas System Polymeric drug delivery systems for treatment of disease
CN108853507A (zh) * 2017-05-11 2018-11-23 复旦大学 一种抗肿瘤的增效药物组合物及其制备方法和用途
WO2019100003A1 (en) * 2017-11-17 2019-05-23 Yoon Jaeyoung Combination therapy targeting cancer associated with the hedgehog pathway

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011513199A (ja) * 2008-02-26 2011-04-28 武田薬品工業株式会社 縮合複素環誘導体およびその用途
JP2013503174A (ja) * 2009-08-25 2013-01-31 アブラクシス バイオサイエンス， エルエルシー タキサンおよびヘッジホッグ阻害剤のナノ粒子組成物を使用する併用療法
US20170119740A1 (en) * 2013-11-14 2017-05-04 The Board Of Trustees Of The Leland Stanford Junior University Methods for Treating Cancer by Activation of BMP Signaling

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DI MAGNO, L. ET AL.: "Digging a hole under Hedgehog: downstream inhibition as an emerging anticancer strategy", BIOCHIM BIOPHYS ACTA., vol. 1856(1):62-72, JPN6024018942, 2015, ISSN: 0005327819 *
KATAGIRI, T. ET AL.: "HIF-1 maintains a functional relationship between pancreatic cancer cells and stromal fibroblasts by", ONCOTARGET, vol. 9(12):10525-10535, JPN6024018941, 2018, ISSN: 0005519669 *
OHASHI, T ET AL.: "Discovery of the investigational drug TAK-441, a pyrrolo[3,2-c]pyridine derivative, as a highly pote", BIOORG MED CHEM., vol. 20(18):5507-17, JPN6024018940, 2012, ISSN: 0005519668 *
PEER E. ET AL.: "Next-Generation Hedgehog/GLI Pathway Inhibitors for Cancer Therapy", CANCERS, vol. 11(4):538, JPN6024018943, April 2019 (2019-04-01), ISSN: 0005327820 *

Also Published As

Publication number Publication date
EP3976036A1 (en) 2022-04-06
IL288591B2 (en) 2026-05-01
KR20220002745A (ko) 2022-01-06
JP2025143272A (ja) 2025-10-01
CA3141072A1 (en) 2020-12-03
IL288591A (en) 2022-02-01
MX2021014686A (es) 2022-04-06
AU2020283913A1 (en) 2022-01-27
CN114126656A (zh) 2022-03-01
US11911374B2 (en) 2024-02-27
EP3976036A4 (en) 2023-04-26
US20220071982A1 (en) 2022-03-10
WO2020243745A1 (en) 2020-12-03
IL288591B1 (en) 2026-01-01
BR112021026294A2 (pt) 2022-03-03
CN119326899A (zh) 2025-01-21

Similar Documents

Publication Publication Date Title
TW202038957A (zh) 抗體-藥物結合物與激酶抑制劑之組合
JP2009538317A (ja) 癌治療のための置換ジアリールウレアを用いた薬物の組み合わせ
KR20180048804A (ko) 바리티닙 및 항암제를 포함하는 병용 요법
TWI762784B (zh) Cdk4/6抑制劑與egfr抑制劑聯合在製備治療腫瘤疾病的藥物中的用途
AU2016285597A1 (en) Combination of HDAC inhibitor and anti-PD-L1 antibody for treatment of cancer
KR20240009437A (ko) 에큐벡테딘 용량 요법
US11701356B2 (en) Treatment of breast cancer using combination therapies comprising an AKT inhibitor, a taxane, and a PD-L1 inhibitor
JP2019514864A (ja) 肝癌の治療方法
US20260091021A1 (en) Combination therapies comprising panobinostat for the treatment of cholangiocarcinoma
CN113939297A (zh) 用于治疗Notch活化的乳腺癌的双氟烷基-1,4-苯并二氮杂卓酮化合物
JP2024521947A (ja) Ｍｃｌ－１阻害剤と抗体薬物コンジュゲートとの組み合わせ
US20250064824A1 (en) Administration of aurora kinase inhibitor and chemotherapeutic agents
WO2021048417A1 (en) Combination therapies comprising dasatinib for the treatment of cholangiocarcinoma
US11911374B2 (en) Methods and uses for treating cancer
HK40122790A (en) Methods and uses for treating cancer
WO2021048419A1 (en) Combination therapies comprising trametinib for the treatment of cholangiocarcinoma
WO2025166537A1 (en) Methods of treatment using an ezh2 modulator
EA050479B1 (ru) Комбинированная терапия с применением ингибиторов prmt5 для лечения рака
EA049653B1 (ru) Комбинированная терапия с применением ингибиторов prmt5 для лечения рака
CN121925259A (zh) 血液癌的新型联合疗法
AU2021200121A1 (en) Pharmaceutical compositions and use thereof for relieving resistance due to cancer chemotherapy and enhancing effect of cancer chemotherapy
CA2530311A1 (en) Cancer treatment with epothilones
Massard et al. 612 MOSCATO: a Molecular Screening Triage Trial for Patients Enrolled in Phase I Trials
TW201016214A (en) Synergistic pharmaceutical composition for the treatment of cancers

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20220218

RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20220218

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230529

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230529

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240521

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240809

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241120

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250204